In this issue:
Ocrelizumab dose reduction in RRMS
Spinal cord lesion formation with DMTs in relapse-onset MS
EvolutionRMS1/2 trials: evobrutinib in relapsing MS
CVS, CL & PRL for diagnosis of MS
Disease activity & neonate outcomes with natalizumab in pregnancy
DMTs & disability worsening in paediatric-onset MS
Serologic responses to EBV peptides & MS risk
Healthy lifestyle behaviours & health outcomes in MS
Baseline sNfL levels to predict aggressive/benign RRMS
MS disease activity in pregnancy after cladribine
Please login below to download this issue (PDF)